1. Beumer JH, Eiseman JL, Parise RA, Joseph E, Holleran JL, Covey JM, Egorin MJ (2006) Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine in mice. Clin Cancer Res 12:7483–7491
2. Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz H, Egorin MJ (2006) Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its metabolites 5-fluoro-2′-deoxyuridine (FdUrd), 5-fluorouracil (FU), 5-fluorouridine (FUrd), and 5-fluorocytosine (FC) in plasma of patients treated with FdCyd. Proc Am Soc Clin Oncol 25:845
3. Boothman DA, Briggle TV, Greer S (1987) Tumor-selective metabolism of 5-fluoro-2′-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma. Cancer Res 47:2354–2362
4. Dareer SM, Mulligan LT Jr, White V, Tillery K, Mellett LB, Hill DL (1977) Distribution of [3H]cytosine arabinoside and its products in mice, dogs, and monkeys and effect of tetrahydrouridine. Cancer Treat Rep 61:395–407
5. BRENDA The comprehensive enzyme information system. http://wwwbrendauni-koelnde/indexphp4 (2005) http://www.brenda.uni-koeln.de/index.php4 . Accessed 28 Nov 2005